Literature DB >> 25976108

Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients.

Ruben Fernandez-Alvarez1, Ana P Gonzalez-Rodriguez2, Arturo Rubio-Castro1, M Esther Gonzalez1, Angel Ramirez Payer2, Ana Alonso-Garcia3, Diana Rodriguez-Villar1, Francisco Dominguez-Iglesias1, Juan M Sancho4.   

Abstract

Entities:  

Year:  2015        PMID： 25976108     DOI： 10.3109/10428194.2015.1050666

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  10 in total

1.  Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.

Authors:  Nivedita Arora; Arjun Gupta; Navid Sadeghi
Journal:  BMJ Case Rep       Date:  2017-10-09

2.  Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis-A Case Report.

Authors:  Anthi Bouchla; Sotirios G Papageorgiou; Zoi Tsakiraki; Eirini Glezou; George Pavlidis; Georgia Stavroulaki; Efthimia Bazani; Periklis Foukas; Vasiliki Pappa
Journal:  Case Rep Hematol       Date:  2018-11-04

Review 3.  Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma.

Authors:  Eva González-Barca; Mónica Coronado; Alejandro Martín; Carlos Montalbán; Santiago Montes-Moreno; Carlos Panizo; Guillermo Rodríguez; Juan Manuel Sancho; Andrés López-Hernández
Journal:  Oncotarget       Date:  2018-08-17

4.  Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma.

Authors:  Jiao Cai; Ling Qiu; Lei Ma; Nan Zhang; Fang-Yi Fan
Journal:  Front Med (Lausanne)       Date:  2021-12-03

5.  A True Mimicker to Plasmacytoma Clinically, Radiologically, and Pathologically - A Rare Case Report.

Authors:  Shino P Ashly; Anu C Thomas; Sajeev S Vadakkedam
Journal:  Asian J Neurosurg       Date:  2021-12-18

6.  Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach.

Authors:  Waleed Sabry; Yue Wu; Shruthi Ganeshappa Kodad
Journal:  Curr Oncol       Date:  2022-07-18       Impact factor: 3.109

Review 7.  Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders.

Authors:  Julie Morscio; Thomas Tousseyn
Journal:  World J Transplant       Date:  2016-09-24

8.  Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets.

Authors:  Sohtaro Mine; Tsunekazu Hishima; Akihiko Suganuma; Hitomi Fukumoto; Yuko Sato; Michiyo Kataoka; Tsuyoshi Sekizuka; Makoto Kuroda; Tadaki Suzuki; Hideki Hasegawa; Masashi Fukayama; Harutaka Katano
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

9.  Plasmablastic lymphoma masquerading solitary plasmacytoma in an immunocompetent patient.

Authors:  Rodrigo Diaz; Julan Amalaseelan; Louise Imlay-Gillespie
Journal:  BMJ Case Rep       Date:  2018-10-21

10.  Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.

Authors:  Lili Cheng; Qi Song; Mengke Liu; Yan Wang; Hongmei Yi; Ying Qian; Pengpeng Xu; Shu Cheng; Chaofu Wang; Li Wang; Weili Zhao
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.